Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Vaccines Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991683
Published Content info 300 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Vaccines Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 300 Pages
Description

North America vaccines market is projected to register a healthy CAGR of 6.6% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

North America Vaccines Market, By Composition (Combination Vaccines, Monovaccines), Type (Subunit, Recombinant, Polysaccharide & Conjugate Vaccines, Live-Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines), Kind (Routine Vaccine, Recommended Vaccine, Required Vaccine), Age of Administration (Pediatric Vaccine, Adult Vaccine), Diseases (Pneumococcal Disease, Measles, Mumps & Varicella, DPT, Hepatitis, Influenza, Typhoid, Meningococcal, Rabies, Japanese Encephalitis, Yellow Fever, Others), Route of Administration (Injectable, Oral, Nasal), End User (Community Hospitals, Hospitals, Specialty Centres, Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy),Country (U.S., Canada , Mexico) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of North America vaccines market are:

  • Increasing government support
  • Presence of pipeline products

Market Players:

The key market players for North America vaccines market are listed below:

  • Emergent BioSolutions Inc.
  • Dynavax Technologies
  • Valneva SE
  • Bavarian Nordic
  • Altimmune
  • Merck Sharp & Dohme Corp (a subsidiary of Merck & Co., Inc.)
  • Takeda Pharmaceutical Company Limited
  • Seqirus (a Subsidiary of CSL Limited),
  • Abbott
  • AstraZeneca
  • Sanofi
  • Pfizer Inc.
  • Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)
  • F. Hoffmann-La Roche Ltd
  • DAIICHI SANKYO COMPANY, LIMITED
  • ALK
  • Panacea Biotec Ltd
  • BAXTER VACCINES (a subsidiary of Baxter)
  • GlaxoSmithKline plc.
  • Serum Institute of India Pvt. Ltd.,
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA VACCINES MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 COMPOSITION LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS

7 NORTH AMERICA VACCINES MARKET: LAWS AND REGULATIONS

8 NORTH AMERICA VACCINES MARKET: LOGISTICS OF VACCINES

8.1 COLD CHAIN STORAGE:

  • 8.2 REGULATIONS ASSOCIATED WITH VACCINE SUPPLY
  • 8.3 PROCESS OF LOGISTICS
  • 8.4 CHALLENGES IN LOGISTICS

8.5 CHALLENGES FACED BY INDIA FOR UPCOMING COVID 19 VACCINE:

8.6 CHALLENGES FACED BY LATIN AMERICA FOR UPCOMING VACCINE:

8.7 CHALLENGES FACED BY NIGERIA FOR VACCINE LOGISTICS:

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS
    • 9.1.2 HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES
    • 9.1.3 IMPROVEMENT IN TREATMENT
    • 9.1.4 LAUNCH OF NEWER VACCINES
    • 9.1.5 INCREASING GOVERNMENT SUPPORT
  • 9.2 RESTRAINTS
    • 9.2.1 UNAVAILABILITY OF REGISTERED VACCINES
    • 9.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES
    • 9.2.3 DIFFICULTIES ASSOCIATED WITH TRANSPORT AND PRODUCTION OF VACCINES
  • 9.3 OPPORTUNITIES
    • 9.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
    • 9.3.2 PRESENCE OF PIPELINE PRODUCTS
    • 9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
    • 9.3.4 INCREASING AWARENESS FOR VACCINATION
  • 9.4 CHALLENGES
    • 9.4.1 SIDE EFFECTS CAUSED BY VACCINES
    • 9.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS
    • 9.4.3 PRODUCT RECALL

10 IMPACT OF COVID-19 ON NORTH AMERICA VACCINES MARKET

  • 10.1 PRICE IMPACT
  • 10.2 IMPACT ON SUPPLY CHAIN
  • 10.3 IMPACT ON DEMAND
  • 10.4 CONCLUSION

11 NORTH AMERICA VACCINES MARKET, BY COMPOSITION

  • 11.1 OVERVIEW
  • 11.2 COMBINATION VACCINES
  • 11.3 MONO VACCINES

12 NORTH AMERICA VACCINES MARKET, BY TYPE

  • 12.1 OVERVIEW
  • 12.2 SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES
    • 12.2.1 PNEUMOCOCCAL DISEASE
    • 12.2.2 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
    • 12.2.3 HPV (HUMAN PAPILLOMA VIRUS)
    • 12.2.4 HEPATITIS B
    • 12.2.5 MENINGOCOCCAL
    • 12.2.6 SHINGLES
    • 12.2.7 WHOOPING COUGH
    • 12.2.8 OTHERS
  • 12.3 LIVE-ATTENUTAED VACCINES
    • 12.3.1 ROTAVIRUS
    • 12.3.2 MEASLES
    • 12.3.3 MUMPS
    • 12.3.4 RUBELLA
    • 12.3.5 SMALLPOX
    • 12.3.6 YELLOW FEVER
    • 12.3.7 OTHERS
  • 12.4 INACTIVATED VACCINES
    • 12.4.1 FLU (SHOT ONLY)
    • 12.4.2 POLIO (SHOT ONLY)
    • 12.4.3 HEPATITIS A
    • 12.4.4 RABIES
    • 12.4.5 OTHERS
  • 12.5 TOXOID VACCINES
    • 12.5.1 DIPHTHERIA, TETANUS & PERTUSSIS (DTP)
    • 12.5.2 OTHERS
  • 12.6 DNA VACCINES

13 NORTH AMERICA VACCINES MARKET, BY KIND

  • 13.1 OVERVIEW
  • 13.2 ROUTINE VACCINE
    • 13.2.1 PNEUMOCOCCAL
    • 13.2.2 DIPHTHERIA
    • 13.2.3 HIB (HAEMOPHILUS INFLUENZAE TYPE B) DISEASE
    • 13.2.4 MEASLES
    • 13.2.5 MUMPS
    • 13.2.6 HEPATITIS B
    • 13.2.7 RUBELLA
    • 13.2.8 POLIO
    • 13.2.9 OTHERS
  • 13.3 RECOMMENDED VACCINES
    • 13.3.1 TYPHOID FEVER VACCINES
    • 13.3.2 HEPATITIS A
    • 13.3.3 RABIES
    • 13.3.4 JAPANESE ENCEPHALITIS
    • 13.3.5 TICK-BORNE ENCEPHALITIS
    • 13.3.6 CHOLERA
    • 13.3.7 OTHERS
  • 13.4 REQUIRED VACCINES
    • 13.4.1 MENINGOCOCCAL
    • 13.4.2 YELLOW FEVER
    • 13.4.3 OTHERS

14 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION

  • 14.1 OVERVIEW
  • 14.2 PEDIATRIC VACCINES
    • 14.2.1 PNEUMOCOCCAL
    • 14.2.2 MEASLES, MUMPS, AND, RUBELLA
    • 14.2.3 DIPHTHERIA, TETANUS & PERTUSIS (DPT)
    • 14.2.4 ROTAVIRUS
    • 14.2.5 MENINGOCOCCAL
    • 14.2.6 VARICELLA
    • 14.2.7 POLIO
    • 14.2.8 TUBERCULOSIS
    • 14.2.9 MALARIA
    • 14.2.10 OTHERS
  • 14.3 ADULT VACCINES
    • 14.3.1 INLFUENZA
    • 14.3.2 HPV (HUMAN PAPILLOMA VIRUS)
    • 14.3.3 TYPHOID
    • 14.3.4 HEPATITIS B
    • 14.3.5 JAPANESE ENCEPHALITIS
    • 14.3.6 YELLOW FEVER
    • 14.3.7 HIV
    • 14.3.8 CANCER
    • 14.3.9 OTHERS

15 NORTH AMERICA VACCINES MARKET, BY DISEASES

  • 15.1 OVERVIEW
  • 15.2 PNEUMOCCOCAL DISEASE
  • 15.3 MEASLES, MUMPS & RUBELLA
  • 15.4 DPT
  • 15.5 HEPATITIS
  • 15.6 INFLUENZA
  • 15.7 TYPHOID
  • 15.8 MENINGOCOCCAL
  • 15.9 VARICELLA
  • 15.10 RABIES
  • 15.11 JAPANESE ENCEPHALITIS
  • 15.12 YELLOW FEVER
  • 15.13 OTHERS

16 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 16.1 OVERVIEW
  • 16.2 INJECTABLE
    • 16.2.1 INTRAMUSCULAR
    • 16.2.2 SUBCUTANEOUS
    • 16.2.3 INTRADERMAL
  • 16.3 ORAL
  • 16.4 NASAL

17 NORTH AMERICA VACCINES MARKET, BY END USER

  • 17.1 OVERVIEW
  • 17.2 COMMUNITY HOSPITALS
  • 17.3 HOSPITALS
  • 17.4 SPECIALTY CENTRES
  • 17.5 CLINICS
  • 17.6 OTHERS

18 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL

  • 18.1 OVERVIEW
  • 18.2 HOSPITAL PHARMACY
  • 18.3 RETAIL PHARMACY
  • 18.4 ONLINE PHARMACY

19 NORTH AMERICA VACCINES MARKET, BY GEOGRAPHY

  • 19.1 NORTH AMERICA
    • 19.1.1 U.S.
    • 19.1.2 CANADA
    • 19.1.3 MEXICO

20 NORTH AMERICA VACCINES MARKET: COMPANY LANDSCAPE

  • 20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

21 COMPANY PROFILE

  • 21.1 GLAXOSMITHKLINE PLC.
    • 21.1.1 COMPANY SNAPSHOT
    • 21.1.2 REVENUE ANALYSIS
    • 21.1.3 COMPANY SHARE ANALYSIS
    • 21.1.4 PRODUCT PORTFOLIO
    • 21.1.5 RECENT DEVELOPMENTS
    • 21.1.6 SWOT ANALYSIS
  • 21.2 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 21.2.1 COMPANY SNAPSHOT
    • 21.2.2 REVENUE ANALYSIS
    • 21.2.3 COMPANY SHARE ANALYSIS
    • 21.2.4 PRODUCT PORTFOLIO
    • 21.2.5 RECENT DEVELOPMENTS
    • 21.2.6 SWOT ANALYS
  • 21.3 SANOFI
    • 21.3.1 COMPANY SNAPSHOT
    • 21.3.2 REVENUE ANALYSIS
    • 21.3.3 COMPANY SHARE ANALYSIS
    • 21.3.4 PRODUCT PORTFOLIO
    • 21.3.5 RECENT DEVELOPMENTS
    • 21.3.6 SWOT ANALYS
  • 21.4 PFIZER INC.
    • 21.4.1 COMPANY SNAPSHOT
    • 21.4.2 REVENUE ANALYSIS
    • 21.4.3 COMPANY SHARE ANALYSIS
    • 21.4.4 PRODUCT PORTFOLIO
    • 21.4.5 RECENT DEVELOPMENTS
    • 21.4.6 SWOT ANAL
  • 21.5 ABBOTT
    • 21.5.1 COMPANY SNAPSHOT
    • 21.5.2 REVENUE ANALYSIS
    • 21.5.3 COMPANY SHARE ANALYSIS
    • 21.5.4 PRODUCT PORTFOLIO
    • 21.5.5 RECENT DEVELOPMENTS
  • 21.6 ALK
    • 21.6.1 COMPANY SNAPSHOT
    • 21.6.2 REVENUE ANALYSIS
    • 21.6.3 PRODUCT PORTFOLIO
    • 21.6.4 RECENT DEVELOPMENTS
  • 21.7 ALTIMMUNE
    • 21.7.1 COMPANY SNAPSHOT
    • 21.7.2 REVENUE ANALYSIS
    • 21.7.3 PRODUCT PORTFOLIO
    • 21.7.4 RECENT DEVELOPMENTS
  • 21.8 ASTRAZENECA
    • 21.8.1 COMPANY SNAPSHOT
    • 21.8.2 REVENUE ANALYSIS
    • 21.8.3 PRODUCT PORTFOLIO
    • 21.8.4 RECENT DEVELOPMENTS
  • 21.9 BAVARIAN NORDIC
    • 21.9.1 COMPANY SNAPSHOT
    • 21.9.2 REVENUE ANALYSIS
    • 21.9.3 PRODUCT PORTFOLIO
    • 21.9.4 RECENT DEVELOPMENTS
  • 21.10 BAXTER VACCINES (A SUBSIDIARY OF BAXTER)
    • 21.10.1 COMPANY SNAPSHOT
    • 21.10.2 REVENUE ANALYSIS
    • 21.10.3 PRODUCT PORTFOLIO
    • 21.10.4 RECENT DEVELOPMENTS
  • 21.11 BHARAT BIOTECH
    • 21.11.1 COMPANY SNAPSHOT
    • 21.11.2 PRODUCT PORTFOLIO
    • 21.11.3 RECENT DEVELOPMENTS
  • 21.12 BIO FARMA
    • 21.12.1 COMPANY SNAPSHOT
    • 21.12.2 PRODUCT PORTFOLIO
    • 21.12.3 RECENT DEVELOPMENTS
  • 21.13 BIOLOGICAL E LIMITED
    • 21.13.1 COMPANY SNAPSHOT
    • 21.13.2 PRODUCT PORTFOLIO
    • 21.13.3 RECENT DEVELOPMENTS
  • 21.14 DAIICHI SANKYO COMPANY, LIMITED
    • 21.14.1 COMPANY SNAPSHOT
    • 21.14.2 REVENUE ANALYSIS
    • 21.14.3 PRODUCT PORTFOLIO
    • 21.14.4 RECENT DEVELOPMENTS
  • 21.15 DYNAVAX TECHNOLOGIES
    • 21.15.1 COMPANY SNAPSHOT
    • 21.15.2 REVENUE ANALYSIS
    • 21.15.3 PRODUCT PORTFOLIO
    • 21.15.4 RECENT DEVELOPMENTS
  • 21.16 EMERGENT BIOSOLUTIONS INC.
    • 21.16.1 COMPANY SNAPSHOT
    • 21.16.2 REVENUE ANALYSIS
    • 21.16.3 PRODUCT PORTFOLIO
    • 21.16.4 RECENT DEVELOPMENTS
  • 21.17 F. HOFFMANN-LA ROCHE LTD
    • 21.17.1 COMPANY SNAPSHOT
    • 21.17.2 REVENUE ANALYSIS
    • 21.17.3 PRODUCT PORTFOLIO
    • 21.17.4 RECENT DEVELOPMENT
  • 21.18 JANSSEN NORTH AMERICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 21.18.1 COMPANY SNAPSHOT
    • 21.18.2 REVENUE ANALYSIS
    • 21.18.3 PRODUCT PORTFOLIO
    • 21.18.4 RECENT DEVELOPMENTS
  • 21.19 LANZHOU BIOLOGICAL PRODUCTS RESEARCH INSTITUTE CO., LTD.,
    • 21.19.1 COMPANY SNAPSHOT
    • 21.19.2 PRODUCT PORTFOLIO
    • 21.19.3 RECENT DEVELOPMENTS
  • 21.20 PANACEA BIOTEC LTD
    • 21.20.1 COMPANY SNAPSHOT
    • 21.20.2 REVENUE ANALYSIS
    • 21.20.3 PRODUCT PORTFOLIO
    • 21.20.4 RECENT DEVELOPMENTS
  • 21.21 SEQIRUS (A SUBSIDIARY OF CSL LIMITED)
    • 21.21.1 COMPANY SNAPSHOT
    • 21.21.2 REVENUE ANALYSIS
    • 21.21.3 PRODUCT PORTFOLIO
    • 21.21.4 RECENT DEVELOPMENTS
    • 21.21.5 SWOT ANALYSIS
  • 21.22 SERUM INSTITUTE OF INDIA PVT. LTD.
    • 21.22.1 COMPANY SNAPSHOT
    • 21.22.2 PRODUCT PORTFOLIO
    • 21.22.3 RECENT DEVELOPMENTS
  • 21.23 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 21.23.1 COMPANY SNAPSHOT
    • 21.23.2 REVENUE ANALYSIS
    • 21.23.3 PRODUCT PORTFOLIO
    • 21.23.4 RECENT DEVELOPMENTS
  • 21.24 VALNEVA SE
    • 21.24.1 COMPANY SNAPSHOT
    • 21.24.2 REVENUE ANALYSIS
    • 21.24.3 PRODUCT PORTFOLIO
    • 21.24.4 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 NORTH AMERICA VACCINES MARKET, PIPELINE ANALYSIS
  • TABLE 2 REGULATIONS IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
  • TABLE 3 RECOMMENDED TEMPERATURE AND STORAGE LENGTH AT VARIOUS LEVEL OF THE COLD CHAIN.
  • TABLE 4 PROCEDURES FOR REPORTING TO UNICEF VACCINE ARRIVALS.
  • TABLE 5 LOGISITCS PROCESS ACORSS DIFFERENT REGIONS.
  • TABLE 6 THE U.S. FUNDING FOR GAVI (2015-2019)
  • TABLE 7 PRICE OF THE VACCINES BETWEEN THE U.S. AND DEVELOPING COUNTRIES
  • TABLE 8 VACCINES UNDER CLINICAL TRIAL
  • TABLE 9 THE SIDE EFFECTS RELATED TO THE VACCINES
  • TABLE 10 INCREASE IN OPERATIONAL COST COMPONENTS DUE TO COVID-19
  • TABLE 11 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
  • TABLE 12 NORTH AMERICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
  • TABLE 13 NORTH AMERICA COMBINATION VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 NORTH AMERICA MONO VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 NORTH AMERICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 16 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 17 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 19 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 21 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 22 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 23 NORTH AMERICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 24 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 25 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 26 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 28 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 30 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 31 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 33 NORTH AMERICA ADULT VACCINE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 NORTH AMERICA ADULT IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 35 NORTH AMERICA PNEUMOCOCCAL DISEASE IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 36 NORTH AMERICA MEASLES, MUMPS & RUBELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 37 NORTH AMERICA DPT IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 38 NORTH AMERICA HEPATITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 39 NORTH AMERICA INFLUENZA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 40 NORTH AMERICA TYPHOID IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 41 NORTH AMERICA MENINGOCOCCAL IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 42 NORTH AMERICA VARICELLA IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA RABIES IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA JAPANESE ENCEPHALITIS IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 45 NORTH AMERICA YELLOW FEVER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 46 NORTH AMERICA OTHER IN VACCINES MARKET, BY REGION, 2017-2028 (USD MILLION)
  • TABLE 47 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 48 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 49 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA ORAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 51 NORTH AMERICA NASAL IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA COMMUNITY HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA HOSPITALS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 55 NORTH AMERICA SPECIALTY CENTRES IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 56 NORTH AMERICA CLINICS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 57 NORTH AMERICA OTHERS IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 58 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 59 NORTH AMERICA HOSPITAL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 60 NORTH AMERICA RETAIL PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 61 NORTH AMERICA ONLINE PHARMACY IN VACCINES MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 62 NORTH AMERICA VACCINES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
  • TABLE 63 NORTH AMERICA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
  • TABLE 64 NORTH AMERICA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 65 NORTH AMERICA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 66 NORTH AMERICA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 67 NORTH AMERICA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 68 NORTH AMERICA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 69 NORTH AMERICA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 70 NORTH AMERICA ROUTINE VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 71 NORTH AMERICA RECOMMENDED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 72 NORTH AMERICA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 73 NORTH AMERICA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 74 NORTH AMERICA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 75 NORTH AMERICA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 76 NORTH AMERICA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
  • TABLE 77 NORTH AMERICA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 78 NORTH AMERICA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 79 NORTH AMERICA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 80 NORTH AMERICA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 81 U.S. VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
  • TABLE 82 U.S. VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 83 U.S. SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 84 U.S. LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 85 U.S. INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 86 U.S. TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 87 U.S. VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 88 U.S. ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 89 U.S. RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 90 U.S. REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 91 U.S. VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 92 U.S. PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 93 U.S. ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 94 U.S. VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
  • TABLE 95 U.S. VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 96 U.S. INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 97 U.S. VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 98 U.S. VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 99 CANADA VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
  • TABLE 100 CANADA VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 101 CANADA SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 102 CANADA LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 103 CANADA INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 104 CANADA TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 105 CANADA VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 106 CANADA ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 107 CANADA RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 108 CANADA REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 109 CANADA VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 110 CANADA PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 111 CANADA ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 112 CANADA VACCINES MARKET, BY DISEASE, 2019-2028 (USD MILLION)
  • TABLE 113 CANADA VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 114 CANADA INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 115 CANADA VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 116 CANADA VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 117 MEXICO VACCINES MARKET, BY COMPOSITION, 2019-2028 (USD MILLION)
  • TABLE 118 MEXICO VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 119 MEXICO SUBUNIT, RECOMBINANT, POLYSACCHARIDE & CONJUGATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 120 MEXICO LIVE-ATTENUATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 121 MEXICO INACTIVATED VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 122 MEXICO TOXOID VACCINES IN VACCINES MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 123 MEXICO VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 124 MEXICO ROUTINE VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 125 MEXICO RECOMMENDED VACCINES IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 126 MEXICO REQUIRED VACCINE IN VACCINES MARKET, BY KIND, 2019-2028 (USD MILLION)
  • TABLE 127 MEXICO VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 128 MEXICO PEDIATRIC VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 129 MEXICO ADULT VACCINE IN VACCINES MARKET, BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 130 MEXICO VACCINES MARKET, BY DISEASES, 2019-2028 (USD MILLION)
  • TABLE 131 MEXICO VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 132 MEXICO INJECTABLE IN VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • TABLE 133 MEXICO VACCINES MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 134 MEXICO VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA VACCINES MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA VACCINES MARKET : DATA TRIANGULATION
  • FIGURE 3 NORTH AMERICA VACCINES MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA VACCINES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA VACCINES MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA VACCINES MARKET: MULTIVARIATE MODELLING
  • FIGURE 7 NORTH AMERICA VACCINES MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 8 NORTH AMERICA VACCINES MARKET: DBMR MARKET POSITION GRID
  • FIGURE 9 NORTH AMERICA VACCINES MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA VACCINES MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 11 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS AND HIGH PREVALENCE OF CHRONIC CONDITION SUCH AS FLU AND BACTERIAL INFECTIOUS DISEASES ARE DRIVING THE NORTH AMERICA VACCINES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 COMBINATION VACCINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA VACCINES MARKET IN 2021 & 2028
  • FIGURE 13 FDA REGULATORY REVIEW PROCESS OF VACCINES
  • FIGURE 14 AEFI ORGANIZATIONAL STRUCTURES
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA VACCINES MARKET
  • FIGURE 16 NORTH AMERICA VACCINATION COVERAGE IN THE WORLD (2019)
  • FIGURE 17 PEDIATRIC DEATHS CAUSED BY INFLUENZA IN THE U.S. (2017 - 2020)
  • FIGURE 18 NORTH AMERICA PREVALENCE OF HBV INFECTION WORLDWIDE IN 2018
  • FIGURE 19 HEALTHCARE EXPENDITURE PER CAPITA, 2018
  • FIGURE 20 TOTAL NUMBER OF CASES FOR MEASLES REPORTED BY THE TEN COUNTRIES
  • FIGURE 21 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, 2021
  • FIGURE 22 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, 2019-2028 (USD MILLION)
  • FIGURE 23 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, CAGR (2021-2028)
  • FIGURE 24 NORTH AMERICA VACCINES MARKET: BY COMPOSITION, LIFELINE CURVE
  • FIGURE 25 NORTH AMERICA VACCINES MARKET: BY TYPE, 2021
  • FIGURE 26 NORTH AMERICA VACCINES MARKET: BY TYPE, 2019-2028 (USD MILLION)
  • FIGURE 27 NORTH AMERICA VACCINES MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 28 NORTH AMERICA VACCINES MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 29 NORTH AMERICA VACCINES MARKET: BY KIND, 2019
  • FIGURE 30 NORTH AMERICA VACCINES MARKET: BY KIND, 2019-2028 (USD MILLION)
  • FIGURE 31 NORTH AMERICA VACCINES MARKET: BY KIND, CAGR (2021-2028)
  • FIGURE 32 NORTH AMERICA VACCINES MARKET: BY KIND, LIFELINE CURVE
  • FIGURE 33 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019
  • FIGURE 34 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • FIGURE 35 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, CAGR (2021-2028)
  • FIGURE 36 NORTH AMERICA VACCINES MARKET: BY AGE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 37 NORTH AMERICA VACCINES MARKET: BY DISEASES, 2020
  • FIGURE 38 NORTH AMERICA VACCINES MARKET: BY DISEASES, 2019-2028 (USD MILLION)
  • FIGURE 39 NORTH AMERICA VACCINES MARKET: BY DISEASES, CAGR (2021-2028)
  • FIGURE 40 NORTH AMERICA VACCINES MARKET: BY DISEASES, LIFELINE CURVE
  • FIGURE 41 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019
  • FIGURE 42 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
  • FIGURE 43 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
  • FIGURE 44 NORTH AMERICA VACCINES MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 45 NORTH AMERICA VACCINES MARKET: BY END USER, 2019
  • FIGURE 46 NORTH AMERICA VACCINES MARKET: BY END USER, 2019-2028 (USD MILLION)
  • FIGURE 47 NORTH AMERICA VACCINES MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 48 NORTH AMERICA VACCINES MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 49 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019
  • FIGURE 50 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • FIGURE 51 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 52 NORTH AMERICA VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 53 NORTH AMERICA VACCINES MARKET: SNAPSHOT (2020)
  • FIGURE 54 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2020)
  • FIGURE 55 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 56 NORTH AMERICA VACCINES MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 57 NORTH AMERICA VACCINES MARKET: BY TYPE (2021-2028)
  • FIGURE 58 NORTH AMERICA VACCINES MARKET: COMPANY SHARE 2020 (%)
Back to Top